αDß2 as a novel target of experimental polymicrobial sepsis.
Front Immunol
; 13: 1059996, 2022.
Article
in En
| MEDLINE
| ID: mdl-36466931
Since sepsis was defined three decades ago, it has been a target of intensive study. However, there is no specific sepsis treatment available, with its high mortality and morbidity. αDß2 (CD11d/CD18) is one of the four ß2 integrin members. Its role in sepsis has been limitedly studied. Using an experimental polymicrobial sepsis model, we found that the deficiency of αDß2 was associated with less lung injury and better outcome, which was in sharp contrast to other ß2 integrin member αLß2 (CD11a/CD18), and αMß2 (CD11b/CD18). This phenotype was supported by a reduction of bacterial loads in αDß2 knockout mice. Further analysis showed that the deficiency of αDß2 led to a reduction of neutrophil cell death as well as an increase in neutrophil phagocytosis in both murine and human systems. Our data showed a unique role of αDß2 among the ß2 integrin members, which would serve as a potential target to improve the outcome of sepsis.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sepsis
/
Lung Injury
Limits:
Animals
/
Humans
Language:
En
Journal:
Front Immunol
Year:
2022
Document type:
Article
Affiliation country:
United States
Country of publication:
Switzerland